Fibroblast growth factor-23 is regulated by 1α,25-dihydroxyvitamin D

Michael T. Collins, John R. Lindsay, Alka Jain, Marilyn H. Kelly, Carolee M. Cutler, Lee S. Weinstein, Jie Liu, Neal S Fedarko, Karen K. Winer

Research output: Contribution to journalArticle

Abstract

Serum FGF-23 regulation was studied in patients with hypoparathyroidism or pseudohypoparathyroidism treated with calcitriol. Serum FGF-23 levels changed in parallel in response to changes in serum 1,25-D, suggesting that FGF-23 may be regulated by 1,25-D. In addition, the phosphaturic effect of FGF-23 may be diminished in the absence of PTH action on the kidney. Introduction: Fibroblast growth factor (FGF)-23 is a recently described hormone that has been shown to be involved in the regulation of phosphate and vitamin D metabolism. The physiologic role of FGF-23 in mineral metabolism and how serum FGF-23 levels are regulated have yet to be elucidated. Three patients with mineral metabolism defects that allowed for the investigation of the regulation of FGF-23 were studied. Materials and Methods: Patient 1 had postsurgical hypoparathyroidism and Munchausen's syndrome and consumed a pharmacologic dose of calcitriol. Patient 2 had postsurgical hypoparathyroidism and fibrous dysplasia of bone. She was treated with increasing doses of calcitriol followed by synthetic PTH(1-34). Patient 3 had pseudohypoparathyroidism type 1B and tertiary hyperparathyroidism. She underwent parathyroidectomy, which was followed by the development of hungry bone syndrome and hypocalcemia, requiring treatment with calcitriol. Serum FGF-23 and serum and urine levels of mineral metabolites were measured in all three patients. Results: Patient 1 had an acute and marked increase in serum FGF-23 (70 to 670 RU/ml; normal range, 18-108 RU/ml) within 24 h in response to high-dose calcitriol administration. Patient 2 showed stepwise increases in serum FGF-23 from 117 to 824 RU/ml in response to increasing serum levels of 1α,25-dihydroxyvitamin D (1,25-D). Finally, before parathyroidectomy, while hypercalcemic, euphosphatemic, with low levels of 1,25-D (10 pg/ml; normal range, 22-67 pg/ml), and with very high serum PTH (863.7 pg/ml; normal range, 6.0-40.0 pg/ml), patient 3 had high serum FGF-23 levels (217 RU/ml). After surgery, while hypocalcemic, euphosphatemic, and with high serum levels of serum 1,25-D (140 pg/ml), FGF-23 levels were higher than preoperative levels (305 RU/ml). It seemed that the phosphaturic effect of FGF-23 was diminished in the absence of PTH or a PTH effect. Conclusions: Serum FGF-23 may be regulated by serum 1,25-D, and its phosphaturic effect may be less in the absence of PTH.

Original languageEnglish (US)
Pages (from-to)1944-1950
Number of pages7
JournalJournal of Bone and Mineral Research
Volume20
Issue number11
DOIs
StatePublished - Nov 2005

Fingerprint

Serum
Calcitriol
Hypoparathyroidism
Minerals
Parathyroidectomy
Reference Values
fibroblast growth factor 23
1,25-dihydroxyvitamin D
Fibrous Dysplasia of Bone
Munchausen Syndrome
Pseudohypoparathyroidism
Hypocalcemia
Hyperparathyroidism
Bone Development
Parathyroid Hormone
Vitamin D
Phosphates
Urine
Hormones
Kidney

Keywords

  • 1α-hydroxylase
  • Fibroblast growth factor-23
  • Fibrous dysplasia
  • Hypoparathyroidism
  • McCune-Albright syndrome
  • Phosphate
  • Phosphaturia
  • Phosphorus
  • Pseudohypoparathyroidism
  • Vitamin D

ASJC Scopus subject areas

  • Surgery

Cite this

Collins, M. T., Lindsay, J. R., Jain, A., Kelly, M. H., Cutler, C. M., Weinstein, L. S., ... Winer, K. K. (2005). Fibroblast growth factor-23 is regulated by 1α,25-dihydroxyvitamin D. Journal of Bone and Mineral Research, 20(11), 1944-1950. https://doi.org/10.1359/JBMR.050718

Fibroblast growth factor-23 is regulated by 1α,25-dihydroxyvitamin D. / Collins, Michael T.; Lindsay, John R.; Jain, Alka; Kelly, Marilyn H.; Cutler, Carolee M.; Weinstein, Lee S.; Liu, Jie; Fedarko, Neal S; Winer, Karen K.

In: Journal of Bone and Mineral Research, Vol. 20, No. 11, 11.2005, p. 1944-1950.

Research output: Contribution to journalArticle

Collins, MT, Lindsay, JR, Jain, A, Kelly, MH, Cutler, CM, Weinstein, LS, Liu, J, Fedarko, NS & Winer, KK 2005, 'Fibroblast growth factor-23 is regulated by 1α,25-dihydroxyvitamin D', Journal of Bone and Mineral Research, vol. 20, no. 11, pp. 1944-1950. https://doi.org/10.1359/JBMR.050718
Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS et al. Fibroblast growth factor-23 is regulated by 1α,25-dihydroxyvitamin D. Journal of Bone and Mineral Research. 2005 Nov;20(11):1944-1950. https://doi.org/10.1359/JBMR.050718
Collins, Michael T. ; Lindsay, John R. ; Jain, Alka ; Kelly, Marilyn H. ; Cutler, Carolee M. ; Weinstein, Lee S. ; Liu, Jie ; Fedarko, Neal S ; Winer, Karen K. / Fibroblast growth factor-23 is regulated by 1α,25-dihydroxyvitamin D. In: Journal of Bone and Mineral Research. 2005 ; Vol. 20, No. 11. pp. 1944-1950.
@article{86787191d33249de9799df7fa9d2210f,
title = "Fibroblast growth factor-23 is regulated by 1α,25-dihydroxyvitamin D",
abstract = "Serum FGF-23 regulation was studied in patients with hypoparathyroidism or pseudohypoparathyroidism treated with calcitriol. Serum FGF-23 levels changed in parallel in response to changes in serum 1,25-D, suggesting that FGF-23 may be regulated by 1,25-D. In addition, the phosphaturic effect of FGF-23 may be diminished in the absence of PTH action on the kidney. Introduction: Fibroblast growth factor (FGF)-23 is a recently described hormone that has been shown to be involved in the regulation of phosphate and vitamin D metabolism. The physiologic role of FGF-23 in mineral metabolism and how serum FGF-23 levels are regulated have yet to be elucidated. Three patients with mineral metabolism defects that allowed for the investigation of the regulation of FGF-23 were studied. Materials and Methods: Patient 1 had postsurgical hypoparathyroidism and Munchausen's syndrome and consumed a pharmacologic dose of calcitriol. Patient 2 had postsurgical hypoparathyroidism and fibrous dysplasia of bone. She was treated with increasing doses of calcitriol followed by synthetic PTH(1-34). Patient 3 had pseudohypoparathyroidism type 1B and tertiary hyperparathyroidism. She underwent parathyroidectomy, which was followed by the development of hungry bone syndrome and hypocalcemia, requiring treatment with calcitriol. Serum FGF-23 and serum and urine levels of mineral metabolites were measured in all three patients. Results: Patient 1 had an acute and marked increase in serum FGF-23 (70 to 670 RU/ml; normal range, 18-108 RU/ml) within 24 h in response to high-dose calcitriol administration. Patient 2 showed stepwise increases in serum FGF-23 from 117 to 824 RU/ml in response to increasing serum levels of 1α,25-dihydroxyvitamin D (1,25-D). Finally, before parathyroidectomy, while hypercalcemic, euphosphatemic, with low levels of 1,25-D (10 pg/ml; normal range, 22-67 pg/ml), and with very high serum PTH (863.7 pg/ml; normal range, 6.0-40.0 pg/ml), patient 3 had high serum FGF-23 levels (217 RU/ml). After surgery, while hypocalcemic, euphosphatemic, and with high serum levels of serum 1,25-D (140 pg/ml), FGF-23 levels were higher than preoperative levels (305 RU/ml). It seemed that the phosphaturic effect of FGF-23 was diminished in the absence of PTH or a PTH effect. Conclusions: Serum FGF-23 may be regulated by serum 1,25-D, and its phosphaturic effect may be less in the absence of PTH.",
keywords = "1α-hydroxylase, Fibroblast growth factor-23, Fibrous dysplasia, Hypoparathyroidism, McCune-Albright syndrome, Phosphate, Phosphaturia, Phosphorus, Pseudohypoparathyroidism, Vitamin D",
author = "Collins, {Michael T.} and Lindsay, {John R.} and Alka Jain and Kelly, {Marilyn H.} and Cutler, {Carolee M.} and Weinstein, {Lee S.} and Jie Liu and Fedarko, {Neal S} and Winer, {Karen K.}",
year = "2005",
month = "11",
doi = "10.1359/JBMR.050718",
language = "English (US)",
volume = "20",
pages = "1944--1950",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Fibroblast growth factor-23 is regulated by 1α,25-dihydroxyvitamin D

AU - Collins, Michael T.

AU - Lindsay, John R.

AU - Jain, Alka

AU - Kelly, Marilyn H.

AU - Cutler, Carolee M.

AU - Weinstein, Lee S.

AU - Liu, Jie

AU - Fedarko, Neal S

AU - Winer, Karen K.

PY - 2005/11

Y1 - 2005/11

N2 - Serum FGF-23 regulation was studied in patients with hypoparathyroidism or pseudohypoparathyroidism treated with calcitriol. Serum FGF-23 levels changed in parallel in response to changes in serum 1,25-D, suggesting that FGF-23 may be regulated by 1,25-D. In addition, the phosphaturic effect of FGF-23 may be diminished in the absence of PTH action on the kidney. Introduction: Fibroblast growth factor (FGF)-23 is a recently described hormone that has been shown to be involved in the regulation of phosphate and vitamin D metabolism. The physiologic role of FGF-23 in mineral metabolism and how serum FGF-23 levels are regulated have yet to be elucidated. Three patients with mineral metabolism defects that allowed for the investigation of the regulation of FGF-23 were studied. Materials and Methods: Patient 1 had postsurgical hypoparathyroidism and Munchausen's syndrome and consumed a pharmacologic dose of calcitriol. Patient 2 had postsurgical hypoparathyroidism and fibrous dysplasia of bone. She was treated with increasing doses of calcitriol followed by synthetic PTH(1-34). Patient 3 had pseudohypoparathyroidism type 1B and tertiary hyperparathyroidism. She underwent parathyroidectomy, which was followed by the development of hungry bone syndrome and hypocalcemia, requiring treatment with calcitriol. Serum FGF-23 and serum and urine levels of mineral metabolites were measured in all three patients. Results: Patient 1 had an acute and marked increase in serum FGF-23 (70 to 670 RU/ml; normal range, 18-108 RU/ml) within 24 h in response to high-dose calcitriol administration. Patient 2 showed stepwise increases in serum FGF-23 from 117 to 824 RU/ml in response to increasing serum levels of 1α,25-dihydroxyvitamin D (1,25-D). Finally, before parathyroidectomy, while hypercalcemic, euphosphatemic, with low levels of 1,25-D (10 pg/ml; normal range, 22-67 pg/ml), and with very high serum PTH (863.7 pg/ml; normal range, 6.0-40.0 pg/ml), patient 3 had high serum FGF-23 levels (217 RU/ml). After surgery, while hypocalcemic, euphosphatemic, and with high serum levels of serum 1,25-D (140 pg/ml), FGF-23 levels were higher than preoperative levels (305 RU/ml). It seemed that the phosphaturic effect of FGF-23 was diminished in the absence of PTH or a PTH effect. Conclusions: Serum FGF-23 may be regulated by serum 1,25-D, and its phosphaturic effect may be less in the absence of PTH.

AB - Serum FGF-23 regulation was studied in patients with hypoparathyroidism or pseudohypoparathyroidism treated with calcitriol. Serum FGF-23 levels changed in parallel in response to changes in serum 1,25-D, suggesting that FGF-23 may be regulated by 1,25-D. In addition, the phosphaturic effect of FGF-23 may be diminished in the absence of PTH action on the kidney. Introduction: Fibroblast growth factor (FGF)-23 is a recently described hormone that has been shown to be involved in the regulation of phosphate and vitamin D metabolism. The physiologic role of FGF-23 in mineral metabolism and how serum FGF-23 levels are regulated have yet to be elucidated. Three patients with mineral metabolism defects that allowed for the investigation of the regulation of FGF-23 were studied. Materials and Methods: Patient 1 had postsurgical hypoparathyroidism and Munchausen's syndrome and consumed a pharmacologic dose of calcitriol. Patient 2 had postsurgical hypoparathyroidism and fibrous dysplasia of bone. She was treated with increasing doses of calcitriol followed by synthetic PTH(1-34). Patient 3 had pseudohypoparathyroidism type 1B and tertiary hyperparathyroidism. She underwent parathyroidectomy, which was followed by the development of hungry bone syndrome and hypocalcemia, requiring treatment with calcitriol. Serum FGF-23 and serum and urine levels of mineral metabolites were measured in all three patients. Results: Patient 1 had an acute and marked increase in serum FGF-23 (70 to 670 RU/ml; normal range, 18-108 RU/ml) within 24 h in response to high-dose calcitriol administration. Patient 2 showed stepwise increases in serum FGF-23 from 117 to 824 RU/ml in response to increasing serum levels of 1α,25-dihydroxyvitamin D (1,25-D). Finally, before parathyroidectomy, while hypercalcemic, euphosphatemic, with low levels of 1,25-D (10 pg/ml; normal range, 22-67 pg/ml), and with very high serum PTH (863.7 pg/ml; normal range, 6.0-40.0 pg/ml), patient 3 had high serum FGF-23 levels (217 RU/ml). After surgery, while hypocalcemic, euphosphatemic, and with high serum levels of serum 1,25-D (140 pg/ml), FGF-23 levels were higher than preoperative levels (305 RU/ml). It seemed that the phosphaturic effect of FGF-23 was diminished in the absence of PTH or a PTH effect. Conclusions: Serum FGF-23 may be regulated by serum 1,25-D, and its phosphaturic effect may be less in the absence of PTH.

KW - 1α-hydroxylase

KW - Fibroblast growth factor-23

KW - Fibrous dysplasia

KW - Hypoparathyroidism

KW - McCune-Albright syndrome

KW - Phosphate

KW - Phosphaturia

KW - Phosphorus

KW - Pseudohypoparathyroidism

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=27444437568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27444437568&partnerID=8YFLogxK

U2 - 10.1359/JBMR.050718

DO - 10.1359/JBMR.050718

M3 - Article

C2 - 16234967

AN - SCOPUS:27444437568

VL - 20

SP - 1944

EP - 1950

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 11

ER -